Selected research
Market Structure
Global Integrin Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Integrin Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Integrin Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Integrin Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Integrin Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Integrin Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Integrin Inhibitors include Grand Pharmaceutical, Yangtze River Pharmaceutical, Tianjin Chase Sun Pharma, SJZ No.4 Pharmaceutical, Lunan Pharma, Kelun Pharma, Huadong Medicin, Bio-Thera Solutions and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Integrin Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Integrin Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Integrin Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Integrin Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.
Integrin Inhibitors Segment by Company
Grand Pharmaceutical
Yangtze River Pharmaceutical
Tianjin Chase Sun Pharma
SJZ No.4 Pharmaceutical
Lunan Pharma
Kelun Pharma
Huadong Medicin
Bio-Thera Solutions
Takeda
Taj Pharmaceuticals
Sandoz
Polpharma Biologics
Novartis
Merck
Medicure
Johnson & Johnson
GlaxoSmithKline
Gland Pharma
Eli Lilly
Correvio
Biogen
Alvotech
Integrin Inhibitors Segment by Type
Antibodies
Small Molecules
Others
Integrin Inhibitors Segment by Application
Cardiovascular Disease
Tumor
Autoimmune Disease
Other
Integrin Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Integrin Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Integrin Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Integrin Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Integrin Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Integrin Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Integrin Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Integrin Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Integrin Inhibitors Industry Trends
Table 2. Integrin Inhibitors Industry Drivers
Table 3. Integrin Inhibitors Industry Opportunities and Challenges
Table 4. Integrin Inhibitors Industry Restraints
Table 5. Global Integrin Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Integrin Inhibitors Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Integrin Inhibitors Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Integrin Inhibitors Sales Market Share by Manufacturers
Table 9. Global Integrin Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Integrin Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Integrin Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Integrin Inhibitors Manufacturers, Product Type & Application
Table 13. Global Integrin Inhibitors Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Integrin Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Antibodies
Table 17. Major Manufacturers of Small Molecules
Table 18. Major Manufacturers of Others
Table 19. Global Integrin Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 20. Global Integrin Inhibitors Sales by Type (2021-2026) & (K Units)
Table 21. Global Integrin Inhibitors Sales by Type (2027-2032) & (K Units)
Table 22. Global Integrin Inhibitors Sales Market Share by Type (2021-2026)
Table 23. Global Integrin Inhibitors Sales Market Share by Type (2027-2032)
Table 24. Global Integrin Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 25. Global Integrin Inhibitors Revenue by Type (2021-2026) & (K Units)
Table 26. Global Integrin Inhibitors Revenue by Type (2027-2032) & (K Units)
Table 27. Global Integrin Inhibitors Revenue Market Share by Type (2021-2026)
Table 28. Global Integrin Inhibitors Revenue Market Share by Type (2027-2032)
Table 29. Major Manufacturers of Cardiovascular Disease
Table 30. Major Manufacturers of Tumor
Table 31. Major Manufacturers of Autoimmune Disease
Table 32. Major Manufacturers of Other
Table 33. Global Integrin Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 34. Global Integrin Inhibitors Sales by Application (2021-2026) & (K Units)
Table 35. Global Integrin Inhibitors Sales by Application (2027-2032) & (K Units)
Table 36. Global Integrin Inhibitors Sales Market Share by Application (2021-2026)
Table 37. Global Integrin Inhibitors Sales Market Share by Application (2027-2032)
Table 38. Global Integrin Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 39. Global Integrin Inhibitors Revenue by Application (2021-2026) & (K Units)
Table 40. Global Integrin Inhibitors Revenue by Application (2027-2032) & (K Units)
Table 41. Global Integrin Inhibitors Revenue Market Share by Application (2021-2026)
Table 42. Global Integrin Inhibitors Revenue Market Share by Application (2027-2032)
Table 43. Global Integrin Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 44. Global Integrin Inhibitors Sales by Region (2021-2026) & (K Units)
Table 45. Global Integrin Inhibitors Sales Market Share by Region (2021-2026)
Table 46. Global Integrin Inhibitors Sales Forecasted by Region (2027-2032) & (K Units)
Table 47. Global Integrin Inhibitors Sales Forecasted Market Share by Region (2027-2032)
Table 48. North America Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 49. North America Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 50. North America Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 51. Europe Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 52. Europe Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 53. Europe Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 54. Asia Pacific Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 55. Asia Pacific Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 56. Asia Pacific Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 57. South America, Middle East and Africa Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 58. South America, Middle East and Africa Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 59. South America, Middle East and Africa Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 60. Global Integrin Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 61. Global Integrin Inhibitors Revenue by Region (2021-2026) & (US$ Million)
Table 62. Global Integrin Inhibitors Revenue by Region (2027-2032) & (US$ Million)
Table 63. Global Integrin Inhibitors Revenue Market Share by Region (2021-2026)
Table 64. Global Integrin Inhibitors Revenue Market Share by Region (2027-2032)
Table 65. Grand Pharmaceutical Company Information
Table 66. Grand Pharmaceutical Business Overview
Table 67. Grand Pharmaceutical Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Grand Pharmaceutical Integrin Inhibitors Product Portfolio
Table 69. Grand Pharmaceutical Recent Development
Table 70. Yangtze River Pharmaceutical Company Information
Table 71. Yangtze River Pharmaceutical Business Overview
Table 72. Yangtze River Pharmaceutical Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Yangtze River Pharmaceutical Integrin Inhibitors Product Portfolio
Table 74. Yangtze River Pharmaceutical Recent Development
Table 75. Tianjin Chase Sun Pharma Company Information
Table 76. Tianjin Chase Sun Pharma Business Overview
Table 77. Tianjin Chase Sun Pharma Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. Tianjin Chase Sun Pharma Integrin Inhibitors Product Portfolio
Table 79. Tianjin Chase Sun Pharma Recent Development
Table 80. SJZ No.4 Pharmaceutical Company Information
Table 81. SJZ No.4 Pharmaceutical Business Overview
Table 82. SJZ No.4 Pharmaceutical Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. SJZ No.4 Pharmaceutical Integrin Inhibitors Product Portfolio
Table 84. SJZ No.4 Pharmaceutical Recent Development
Table 85. Lunan Pharma Company Information
Table 86. Lunan Pharma Business Overview
Table 87. Lunan Pharma Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Lunan Pharma Integrin Inhibitors Product Portfolio
Table 89. Lunan Pharma Recent Development
Table 90. Kelun Pharma Company Information
Table 91. Kelun Pharma Business Overview
Table 92. Kelun Pharma Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Kelun Pharma Integrin Inhibitors Product Portfolio
Table 94. Kelun Pharma Recent Development
Table 95. Huadong Medicin Company Information
Table 96. Huadong Medicin Business Overview
Table 97. Huadong Medicin Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. Huadong Medicin Integrin Inhibitors Product Portfolio
Table 99. Huadong Medicin Recent Development
Table 100. Bio-Thera Solutions Company Information
Table 101. Bio-Thera Solutions Business Overview
Table 102. Bio-Thera Solutions Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. Bio-Thera Solutions Integrin Inhibitors Product Portfolio
Table 104. Bio-Thera Solutions Recent Development
Table 105. Takeda Company Information
Table 106. Takeda Business Overview
Table 107. Takeda Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Takeda Integrin Inhibitors Product Portfolio
Table 109. Takeda Recent Development
Table 110. Taj Pharmaceuticals Company Information
Table 111. Taj Pharmaceuticals Business Overview
Table 112. Taj Pharmaceuticals Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. Taj Pharmaceuticals Integrin Inhibitors Product Portfolio
Table 114. Taj Pharmaceuticals Recent Development
Table 115. Sandoz Company Information
Table 116. Sandoz Business Overview
Table 117. Sandoz Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. Sandoz Integrin Inhibitors Product Portfolio
Table 119. Sandoz Recent Development
Table 120. Polpharma Biologics Company Information
Table 121. Polpharma Biologics Business Overview
Table 122. Polpharma Biologics Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. Polpharma Biologics Integrin Inhibitors Product Portfolio
Table 124. Polpharma Biologics Recent Development
Table 125. Novartis Company Information
Table 126. Novartis Business Overview
Table 127. Novartis Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. Novartis Integrin Inhibitors Product Portfolio
Table 129. Novartis Recent Development
Table 130. Merck Company Information
Table 131. Merck Business Overview
Table 132. Merck Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 133. Merck Integrin Inhibitors Product Portfolio
Table 134. Merck Recent Development
Table 135. Medicure Company Information
Table 136. Medicure Business Overview
Table 137. Medicure Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 138. Medicure Integrin Inhibitors Product Portfolio
Table 139. Medicure Recent Development
Table 140. Johnson & Johnson Company Information
Table 141. Johnson & Johnson Business Overview
Table 142. Johnson & Johnson Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 143. Johnson & Johnson Integrin Inhibitors Product Portfolio
Table 144. Johnson & Johnson Recent Development
Table 145. GlaxoSmithKline Company Information
Table 146. GlaxoSmithKline Business Overview
Table 147. GlaxoSmithKline Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 148. GlaxoSmithKline Integrin Inhibitors Product Portfolio
Table 149. GlaxoSmithKline Recent Development
Table 150. Gland Pharma Company Information
Table 151. Gland Pharma Business Overview
Table 152. Gland Pharma Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 153. Gland Pharma Integrin Inhibitors Product Portfolio
Table 154. Gland Pharma Recent Development
Table 155. Eli Lilly Company Information
Table 156. Eli Lilly Business Overview
Table 157. Eli Lilly Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 158. Eli Lilly Integrin Inhibitors Product Portfolio
Table 159. Eli Lilly Recent Development
Table 160. Correvio Company Information
Table 161. Correvio Business Overview
Table 162. Correvio Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 163. Correvio Integrin Inhibitors Product Portfolio
Table 164. Correvio Recent Development
Table 165. Biogen Company Information
Table 166. Biogen Business Overview
Table 167. Biogen Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 168. Biogen Integrin Inhibitors Product Portfolio
Table 169. Biogen Recent Development
Table 170. Alvotech Company Information
Table 171. Alvotech Business Overview
Table 172. Alvotech Integrin Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 173. Alvotech Integrin Inhibitors Product Portfolio
Table 174. Alvotech Recent Development
Table 175. Key Raw Materials
Table 176. Raw Materials Key Suppliers
Table 177. Integrin Inhibitors Distributors List
Table 178. Integrin Inhibitors Customers List
Table 179. Research Programs/Design for This Report
Table 180. Authors List of This Report
Table 181. Secondary Sources
Table 182. Primary Sources
List of Figures
Figure 1. Integrin Inhibitors Product Image
Figure 2. Global Integrin Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Integrin Inhibitors Market Size (2021-2032) & (US$ Million)
Figure 4. Global Integrin Inhibitors Sales (2021-2032) & (K Units)
Figure 5. Global Integrin Inhibitors Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Integrin Inhibitors Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Antibodies Image
Figure 9. Small Molecules Image
Figure 10. Others Image
Figure 11. Global Integrin Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 12. Global Integrin Inhibitors Sales Market Share 2021 VS 2025 VS 2032
Figure 13. Global Integrin Inhibitors Sales Market Share by Type (2021-2032)
Figure 14. Global Integrin Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 15. Global Integrin Inhibitors Revenue Market Share 2021 VS 2025 VS 2032
Figure 16. Global Integrin Inhibitors Revenue Market Share by Type (2021-2032)
Figure 17. Cardiovascular Disease Image
Figure 18. Tumor Image
Figure 19. Autoimmune Disease Image
Figure 20. Other Image
Figure 21. Global Integrin Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 22. Global Integrin Inhibitors Sales Market Share 2021 VS 2025 VS 2032
Figure 23. Global Integrin Inhibitors Sales Market Share by Application (2021-2032)
Figure 24. Global Integrin Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 25. Global Integrin Inhibitors Revenue Market Share 2021 VS 2025 VS 2032
Figure 26. Global Integrin Inhibitors Revenue Market Share by Application (2021-2032)
Figure 27. North America Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 28. North America Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 29. U.S. Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 30. Canada Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. Mexico Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 32. Europe Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. Europe Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 34. Germany Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. France Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. U.K. Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. Italy Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. Netherlands Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. Asia Pacific Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Asia Pacific Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 41. China Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. Japan Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. South Korea Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. Southeast Asia Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. India Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. Australia Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. South America, Middle East and Africa Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. South America, Middle East and Africa Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 49. Brazil Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. South Africa Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. Saudi Arabia Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. Turkey Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. Argentina Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. UAE Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Egypt Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. Chile Integrin Inhibitors Sales and Growth Rate (2021-2032) & (K Units)
Figure 57. Global Integrin Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 58. Global Integrin Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 59. North America Integrin Inhibitors Revenue (2021-2032) & (US$ Million)
Figure 60. North America Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 61. Europe Integrin Inhibitors Revenue (2021-2032) & (US$ Million)
Figure 62. Europe Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. Asia-Pacific Integrin Inhibitors Revenue (2021-2032) & (US$ Million)
Figure 64. Asia-Pacific Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. South America, Middle East and Africa Integrin Inhibitors Revenue (2021-2032) & (US$ Million)
Figure 66. South America, Middle East and Africa Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 67. Integrin Inhibitors Value Chain
Figure 68. Manufacturing Cost Structure
Figure 69. Integrin Inhibitors Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Years Considered
Figure 73. Research Process
Figure 74. Key Executives Interviewed
Scope & coverage.
Types
- Antibodies
- Small Molecules
- Others
Applications
- Cardiovascular Disease
- Tumor
- Autoimmune Disease
- Other
Companies covered
- Grand Pharmaceutical
- Yangtze River Pharmaceutical
- Tianjin Chase Sun Pharma
- SJZ No.4 Pharmaceutical
- Lunan Pharma
- Kelun Pharma
- Huadong Medicin
- Bio-Thera Solutions
- Takeda
- Taj Pharmaceuticals
- Sandoz
- Polpharma Biologics
- Novartis
- Merck
- Medicure
- Johnson & Johnson
- GlaxoSmithKline
- Gland Pharma
- Eli Lilly
- Correvio
- Biogen
- Alvotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Integrin Inhibitors Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Integrin Inhibitors Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Integrin Inhibitors Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Integrin Inhibitors Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Integrin Inhibitors Market Dynamics
- 2.1 Integrin Inhibitors Industry Trends
- 2.2 Integrin Inhibitors Industry Drivers
- 2.3 Integrin Inhibitors Industry Opportunities and Challenges
- 2.4 Integrin Inhibitors Industry Restraints
3 Integrin Inhibitors Market by Manufacturers
- 3.1 Global Integrin Inhibitors Revenue by Manufacturers (2021-2026)
- 3.2 Global Integrin Inhibitors Sales by Manufacturers (2021-2026)
- 3.3 Global Integrin Inhibitors Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Integrin Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Integrin Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Integrin Inhibitors Manufacturers, Product Type & Application
- 3.7 Global Integrin Inhibitors Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Integrin Inhibitors Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Integrin Inhibitors Players Market Share by Revenue in 2025
- 3.8.3 2025 Integrin Inhibitors Tier 1, Tier 2, and Tier 3
4 Integrin Inhibitors Market by Type
- 4.1 Integrin Inhibitors Type Introduction
- 4.1.1 Antibodies
- 4.1.2 Small Molecules
- 4.1.3 Others
- 4.2 Global Integrin Inhibitors Sales by Type
- 4.2.1 Global Integrin Inhibitors Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Integrin Inhibitors Sales by Type (2021-2032)
- 4.2.3 Global Integrin Inhibitors Sales Market Share by Type (2021-2032)
- 4.3 Global Integrin Inhibitors Revenue by Type
- 4.3.1 Global Integrin Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Integrin Inhibitors Revenue by Type (2021-2032)
- 4.3.3 Global Integrin Inhibitors Revenue Market Share by Type (2021-2032)
5 Integrin Inhibitors Market by Application
- 5.1 Integrin Inhibitors Application Introduction
- 5.1.1 Cardiovascular Disease
- 5.1.2 Tumor
- 5.1.3 Autoimmune Disease
- 5.1.4 Other
- 5.2 Global Integrin Inhibitors Sales by Application
- 5.2.1 Global Integrin Inhibitors Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Integrin Inhibitors Sales by Application (2021-2032)
- 5.2.3 Global Integrin Inhibitors Sales Market Share by Application (2021-2032)
- 5.3 Global Integrin Inhibitors Revenue by Application
- 5.3.1 Global Integrin Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Integrin Inhibitors Revenue by Application (2021-2032)
- 5.3.3 Global Integrin Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Integrin Inhibitors Sales by Region
- 6.1 Global Integrin Inhibitors Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Integrin Inhibitors Sales by Region (2021-2032)
- 6.2.1 Global Integrin Inhibitors Sales by Region (2021-2026)
- 6.2.2 Global Integrin Inhibitors Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Integrin Inhibitors Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Integrin Inhibitors Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Integrin Inhibitors Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Integrin Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Integrin Inhibitors Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Integrin Inhibitors Revenue by Region
- 7.1 Global Integrin Inhibitors Revenue by Region
- 7.1.1 Global Integrin Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Integrin Inhibitors Revenue by Region (2021-2026)
- 7.1.3 Global Integrin Inhibitors Revenue by Region (2027-2032)
- 7.1.4 Global Integrin Inhibitors Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Integrin Inhibitors Revenue (2021-2032)
- 7.2.2 North America Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Integrin Inhibitors Revenue (2021-2032)
- 7.3.2 Europe Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Integrin Inhibitors Revenue (2021-2032)
- 7.4.2 Asia-Pacific Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Integrin Inhibitors Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Integrin Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Grand Pharmaceutical
- 8.1.1 Grand Pharmaceutical Company Information
- 8.1.2 Grand Pharmaceutical Business Overview
- 8.1.3 Grand Pharmaceutical Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Grand Pharmaceutical Integrin Inhibitors Product Portfolio
- 8.1.5 Grand Pharmaceutical Recent Developments
- 8.2 Yangtze River Pharmaceutical
- 8.2.1 Yangtze River Pharmaceutical Company Information
- 8.2.2 Yangtze River Pharmaceutical Business Overview
- 8.2.3 Yangtze River Pharmaceutical Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Yangtze River Pharmaceutical Integrin Inhibitors Product Portfolio
- 8.2.5 Yangtze River Pharmaceutical Recent Developments
- 8.3 Tianjin Chase Sun Pharma
- 8.3.1 Tianjin Chase Sun Pharma Company Information
- 8.3.2 Tianjin Chase Sun Pharma Business Overview
- 8.3.3 Tianjin Chase Sun Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Tianjin Chase Sun Pharma Integrin Inhibitors Product Portfolio
- 8.3.5 Tianjin Chase Sun Pharma Recent Developments
- 8.4 SJZ No.4 Pharmaceutical
- 8.4.1 SJZ No.4 Pharmaceutical Company Information
- 8.4.2 SJZ No.4 Pharmaceutical Business Overview
- 8.4.3 SJZ No.4 Pharmaceutical Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 SJZ No.4 Pharmaceutical Integrin Inhibitors Product Portfolio
- 8.4.5 SJZ No.4 Pharmaceutical Recent Developments
- 8.5 Lunan Pharma
- 8.5.1 Lunan Pharma Company Information
- 8.5.2 Lunan Pharma Business Overview
- 8.5.3 Lunan Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Lunan Pharma Integrin Inhibitors Product Portfolio
- 8.5.5 Lunan Pharma Recent Developments
- 8.6 Kelun Pharma
- 8.6.1 Kelun Pharma Company Information
- 8.6.2 Kelun Pharma Business Overview
- 8.6.3 Kelun Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Kelun Pharma Integrin Inhibitors Product Portfolio
- 8.6.5 Kelun Pharma Recent Developments
- 8.7 Huadong Medicin
- 8.7.1 Huadong Medicin Company Information
- 8.7.2 Huadong Medicin Business Overview
- 8.7.3 Huadong Medicin Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Huadong Medicin Integrin Inhibitors Product Portfolio
- 8.7.5 Huadong Medicin Recent Developments
- 8.8 Bio-Thera Solutions
- 8.8.1 Bio-Thera Solutions Company Information
- 8.8.2 Bio-Thera Solutions Business Overview
- 8.8.3 Bio-Thera Solutions Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Bio-Thera Solutions Integrin Inhibitors Product Portfolio
- 8.8.5 Bio-Thera Solutions Recent Developments
- 8.9 Takeda
- 8.9.1 Takeda Company Information
- 8.9.2 Takeda Business Overview
- 8.9.3 Takeda Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Takeda Integrin Inhibitors Product Portfolio
- 8.9.5 Takeda Recent Developments
- 8.10 Taj Pharmaceuticals
- 8.10.1 Taj Pharmaceuticals Company Information
- 8.10.2 Taj Pharmaceuticals Business Overview
- 8.10.3 Taj Pharmaceuticals Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Taj Pharmaceuticals Integrin Inhibitors Product Portfolio
- 8.10.5 Taj Pharmaceuticals Recent Developments
- 8.11 Sandoz
- 8.11.1 Sandoz Company Information
- 8.11.2 Sandoz Business Overview
- 8.11.3 Sandoz Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Sandoz Integrin Inhibitors Product Portfolio
- 8.11.5 Sandoz Recent Developments
- 8.12 Polpharma Biologics
- 8.12.1 Polpharma Biologics Company Information
- 8.12.2 Polpharma Biologics Business Overview
- 8.12.3 Polpharma Biologics Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Polpharma Biologics Integrin Inhibitors Product Portfolio
- 8.12.5 Polpharma Biologics Recent Developments
- 8.13 Novartis
- 8.13.1 Novartis Company Information
- 8.13.2 Novartis Business Overview
- 8.13.3 Novartis Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Novartis Integrin Inhibitors Product Portfolio
- 8.13.5 Novartis Recent Developments
- 8.14 Merck
- 8.14.1 Merck Company Information
- 8.14.2 Merck Business Overview
- 8.14.3 Merck Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Merck Integrin Inhibitors Product Portfolio
- 8.14.5 Merck Recent Developments
- 8.15 Medicure
- 8.15.1 Medicure Company Information
- 8.15.2 Medicure Business Overview
- 8.15.3 Medicure Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Medicure Integrin Inhibitors Product Portfolio
- 8.15.5 Medicure Recent Developments
- 8.16 Johnson & Johnson
- 8.16.1 Johnson & Johnson Company Information
- 8.16.2 Johnson & Johnson Business Overview
- 8.16.3 Johnson & Johnson Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Johnson & Johnson Integrin Inhibitors Product Portfolio
- 8.16.5 Johnson & Johnson Recent Developments
- 8.17 GlaxoSmithKline
- 8.17.1 GlaxoSmithKline Company Information
- 8.17.2 GlaxoSmithKline Business Overview
- 8.17.3 GlaxoSmithKline Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 GlaxoSmithKline Integrin Inhibitors Product Portfolio
- 8.17.5 GlaxoSmithKline Recent Developments
- 8.18 Gland Pharma
- 8.18.1 Gland Pharma Company Information
- 8.18.2 Gland Pharma Business Overview
- 8.18.3 Gland Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Gland Pharma Integrin Inhibitors Product Portfolio
- 8.18.5 Gland Pharma Recent Developments
- 8.19 Eli Lilly
- 8.19.1 Eli Lilly Company Information
- 8.19.2 Eli Lilly Business Overview
- 8.19.3 Eli Lilly Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Eli Lilly Integrin Inhibitors Product Portfolio
- 8.19.5 Eli Lilly Recent Developments
- 8.20 Correvio
- 8.20.1 Correvio Company Information
- 8.20.2 Correvio Business Overview
- 8.20.3 Correvio Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Correvio Integrin Inhibitors Product Portfolio
- 8.20.5 Correvio Recent Developments
- 8.21 Biogen
- 8.21.1 Biogen Company Information
- 8.21.2 Biogen Business Overview
- 8.21.3 Biogen Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.21.4 Biogen Integrin Inhibitors Product Portfolio
- 8.21.5 Biogen Recent Developments
- 8.22 Alvotech
- 8.22.1 Alvotech Company Information
- 8.22.2 Alvotech Business Overview
- 8.22.3 Alvotech Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.22.4 Alvotech Integrin Inhibitors Product Portfolio
- 8.22.5 Alvotech Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Integrin Inhibitors Value Chain Analysis
- 9.1.1 Integrin Inhibitors Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Integrin Inhibitors Production Mode & Process
- 9.2 Integrin Inhibitors Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Integrin Inhibitors Distributors
- 9.2.3 Integrin Inhibitors Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst